Advertisement
Advertisement

REVB

REVB logo

Revelation Biosciences, Inc. Common Stock

2.04
USD
Sponsored
+0.14
+7.11%
Jan 30, 15:58 UTC -5
Closed
exchange

After-Market

1.86

-0.17
-8.35%

REVB Earnings Reports

Positive Surprise Ratio

REVB beat 10 of 15 last estimates.

67%

Next Report

Date of Next Report
Mar 04, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$3.73
Implied change from Q3 25 (Revenue/ EPS)
--
/
-47.32%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-75.03%

Revelation Biosciences, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, REVB reported earnings of -7.08 USD per share (EPS) for Q3 25, missing the estimate of -5.44 USD, resulting in a -29.98% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.91% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analysts forecast an EPS of -3.73 USD, with revenue projected to reach -- USD, implying an decrease of -47.32% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Revelation Biosciences, Inc. Common Stock reported EPS of -$7.08, missing estimates by -29.98%, and revenue of $0.00, 0% as expectations.
The stock price moved down -2.91%, changed from $1.01 before the earnings release to $0.98 the day after.
The next earning report is scheduled for Mar 04, 2026.
Based on 4 analysts, Revelation Biosciences, Inc. Common Stock is expected to report EPS of -$3.73 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement